default author photo

Christophe Louvet

Institut Mutualiste Montsouris

SCHOLARLY PAPERS

2

DOWNLOADS

82

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Early Clinical and Molecular Biomarkers in Advanced Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: Chiva Phase Ii Gineco Trial

Number of pages: 22 Posted: 07 Oct 2024
University of Paris-Saclay - Institut Gustave Roussy, University of Paris-Saclay - Institut Gustave Roussy, Université Lyon 1 - Faculty of Medicine Lyon-Sud, affiliation not provided to SSRN, University of Claude Bernard Lyon 1 - Medical Oncology Department, affiliation not provided to SSRN, University of Lille II - Centre Oscar Lambret, Université de Caen, Institut Claudius Regaud, affiliation not provided to SSRN, Université Lyon 1 - Faculty of Medicine Lyon-Sud, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Bordeaux - Institut Bergonié, University of Limoges - CHU Limoges, affiliation not provided to SSRN, Institut Mutualiste Montsouris, Western Cancer Institute, ARCAGY-GINECO, Gustave Roussy, Gustave Roussy, affiliation not provided to SSRN, Gustave Roussy and Université Paris XI Sud - Gustave Roussy Cancer Campus
Downloads 46 (1,109,210)

Abstract:

Loading...

Ovarian cancer, neoadjuvant chemotherapy, biomarkers, homologous recombination deficiency, TILS

2.

Time to Recurrence and its Relation to Survival after Recurrence in Patients Resected for Stage III Colon Cancer

Number of pages: 27 Posted: 18 Jul 2023
Université Paris Cité, Universite Paris Descartes, Sorbonne University, University of Besançon - University Hospital Besançon, INSERM UMR 1231 CADIR, Université Paris Cité, CHU de Reims, Hospital Center University Pontchaillou, Clinique Sainte-Catherine, University of Paris-Saclay - Hôpital Foch, Institut Mutualiste Montsouris, Sorbonne University - Hôpital Pitié-Salpêtrière, Department of Gastroenterology, University of Besançon - University Hospital Besançon, University of Besançon - University Hospital Besançon, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS) and Université Paris Cité
Downloads 36 (1,236,159)

Abstract:

Loading...

Stage III colon cancer, RAS mutation, BRAFV600E mutation, MSI/dMMR, adjuvant, survival after relapse, time to recurrence